InterCure (INCR) Stock Price, News & Analysis

Company Overview

InterCure Ltd is an Israel-based medical cannabis company publicly listed on the Nasdaq Capital Market under the ticker INCR. The company’s operations span the entire value chain of medical cannabis, from the development of proprietary seed strains and controlled cultivation in a GMP-compliant facility to laboratory testing, cannabinoid extraction and formulation. InterCure serves licensed pharmacies and clinics within Israel and adheres to the regulatory framework established by the Israeli Ministry of Health.

Founded in 2013, InterCure has built a vertically integrated platform that supports both patient care and research initiatives. The company’s in-house R&D team works in collaboration with academic and medical institutions to explore novel therapeutic applications of cannabinoids. InterCure’s product portfolio includes standardized oils, capsules and topical formulations designed to address specific clinical indications and patient preferences.

Beyond its domestic footprint, InterCure has entered strategic partnerships aimed at exporting medical cannabis products to select European and Latin American markets. These collaborations are structured to meet local regulatory requirements and quality standards, offering a pathway for InterCure’s intellectual property and high-potency strains to reach new patient populations.

Looking forward, InterCure is focused on scaling its production capacity, enhancing process efficiencies and expanding its international presence through licensing agreements and joint ventures. The company continues to invest in clinical research, advanced processing technologies and new product development as it seeks to establish a broader footprint in the evolving global medical cannabis industry.

Key Stats

• Today's Range: $1.46 to $1.51
• 50-Day Range: $1.44 to $1.73
• 52-Week Range: $1.17 to $2.01
• Volume: 95,170 shs
• Average Volume: 22,948 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

InterCure Stock Analysis - MarketRank™

InterCure scored higher than 9% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for InterCure.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

InterCure has a P/B Ratio of 0.63. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.11% of the float of InterCure has been sold short.

Short Interest Ratio / Days to Cover

InterCure has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in InterCure has recently increased by 12.08%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

InterCure does not currently pay a dividend.

Dividend Growth

InterCure does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.11% of the float of InterCure has been sold short.

Short Interest Ratio / Days to Cover

InterCure has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in InterCure has recently increased by 12.08%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 0.34

News Sentiment

InterCure has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for InterCure this week, compared to 0 articles on an average week.

MarketBeat Follows

1 people have added InterCure to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, InterCure insiders have not sold or bought any company stock.

Percentage Held by Institutions

Only 8.34% of the stock of InterCure is held by institutions.

INCR Stock Analysis - Frequently Asked Questions

How have INCR shares performed this year?

InterCure's stock was trading at $1.59 at the start of the year. Since then, INCR stock has decreased by 6.9% and is now trading at $1.48.

How do I buy shares of InterCure?

Shares of INCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of InterCure own?

Based on aggregate information from My MarketBeat watchlists, some other companies that InterCure investors own include NVIDIA (NVDA), Meta Platforms (META), PayPal (PYPL), Advanced Micro Devices (AMD), Tesla (TSLA), Innovative Industrial Properties (IIPR) and AbbVie (ABBV).

Company Calendar

• Today: 9/22/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:INCR
• CIK: 1857030
• Web: www.intercure.co
• Phone: 972774605012
• Fax: N/A
• Employees: 350
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.34
• Current Ratio: 1.73
• Quick Ratio: 1.18

Sales & Book Value

• Annual Sales: $66.28 million
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.36 per share
• Price / Book: 0.63

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Optionable
• Beta: 1.19